{"id":5942,"date":"2025-06-09T21:21:42","date_gmt":"2025-06-09T19:21:42","guid":{"rendered":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/?page_id=5942"},"modified":"2026-05-05T20:59:22","modified_gmt":"2026-05-05T18:59:22","slug":"stock-market-information","status":"publish","type":"page","link":"https:\/\/bioceltix.com\/en\/investor-relations\/stock-market-information\/","title":{"rendered":"Stock Market Information"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Stock Market Information<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tGo back to Investor Relations<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tImportant financial data<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tFinancial statements<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tInformation<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Important financial data<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\u00a0<\/td>Particulars<\/td>31.12.2025<\/td>31.12.2024<\/td><\/tr>
in PLN<\/span><\/td>in EUR<\/td>in PLN<\/td>in EUR<\/span><\/td><\/tr><\/thead>
1.<\/td>Net revenues from product sales<\/td>0,00<\/td>0,00<\/td>0,00<\/td>0,00<\/td><\/tr>
2.<\/td>Operating profit (loss)<\/td>-15 269 847,55<\/td>-3 603 758,98<\/td>-15 033 836,30<\/td>-3 492 829,40<\/td><\/tr>
3.<\/td>Gross profit (loss)<\/td>-15 205 972,39<\/td>-3 588 684,13<\/td>-14 867 409,31<\/td>-3 454 163,21<\/td><\/tr>
4.<\/td>Net profit (loss)<\/td>-15 190 590,97<\/td>-3 585 054,04<\/td>-14 897 938,22<\/td>-3 461 256,03<\/td><\/tr>
5.<\/td>Net cash flow from operating activities<\/td>-11 949 717,19<\/td>-2 820 191,92<\/td>-17 567 378,33<\/td>-4 081 450,29<\/td><\/tr>
6.<\/td>Net cash flow from investing activities<\/span><\/td>-1 970 196,05<\/td>-464 975,94<\/td>-84 243,74<\/td>-19 572,45<\/td><\/tr>
7.<\/td>Net cash flow from financing activities<\/span><\/td>48 688 831,45<\/td>11 490 803,23<\/td>41 974 179,98<\/td>9 751 912,08<\/td><\/tr>
8.<\/td>Total net cash flow<\/span><\/td>34 768 918,21<\/td>8 205 635,37<\/td>24 322 557,91<\/td>5 650 889,34<\/td><\/tr>
9.<\/td>Net earnings (loss) per ordinary share (in PLN\/EUR)<\/span><\/td>-3,04<\/td>-0,72<\/td>-3,28<\/td>-0,76<\/td><\/tr>
10.<\/td>Diluted net earnings (loss) per ordinary share (in PLN\/EUR)<\/span><\/td>-3,04<\/td>-0,72<\/td>-3,28<\/td>-0,76<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00a0<\/p>
\u00a0<\/td>Particulars<\/span><\/td>31.12.2025<\/td>31.12.2024<\/td><\/tr>
in PLN<\/span><\/td>in EUR<\/span><\/td>in PLN<\/span><\/td>in EUR<\/span><\/td><\/tr><\/thead>
1.<\/td>Total assets<\/span><\/td>75 631 714,56<\/td>17 893 797,65<\/td>41 854 211,16<\/td>9 795 041,23<\/td><\/tr>
\u2013 including cash<\/span><\/td>68 401 758,68<\/td>16 183 253,76<\/td>33 632 840,47<\/td>7 871 013,45<\/td><\/tr>
2.<\/td>Liabilities and provisions for liabilities<\/span><\/td>2 355 278,60<\/td>557 238,18<\/td>3 436 106,39<\/td>804 143,78<\/td><\/tr>
3.<\/td>Long-term liabilities<\/span><\/td>87 574,18<\/td>20 719,28<\/td>149 551,18<\/td>34 999,11<\/td><\/tr>
4.<\/td>Short-term liabilities<\/span><\/td>1 809 831,65<\/td>428 190,23<\/td>2 910 247,92<\/td>681 078,38<\/td><\/tr>
5.<\/td>Equity<\/span><\/td>73 276 435,96<\/td>17 336 559,48<\/td>38 418 104,77<\/td>8 990 897,44<\/td><\/tr>
6.<\/td>Share capital<\/span><\/td>553 225,30<\/td>130 888,23<\/td>492 446,80<\/td>115 246,15<\/td><\/tr>
7.<\/td>Number of shares (pcs.)<\/span><\/td>4 924 468<\/td>4 924 468,00<\/td><\/tr>
8.<\/td>Weighted average number of shares (pcs.)<\/span><\/td>4 998 792<\/td>4 536 770,00<\/td><\/tr>
9.<\/td>Book value per share (PLN\/EUR)<\/span><\/td>14,87<\/td>3,52<\/td>7,80<\/td>1,83<\/td><\/tr>
10.<\/td>Diluted book value per share (PLN\/EUR)<\/td>13,24<\/td>3,13<\/td>7,80<\/td>1,83<\/td><\/tr>
EUR rates<\/td>on average over the period<\/td>4,2372<\/td>4,3042<\/td><\/tr>
from the last day of the period<\/td>4,2267<\/td>4,2730<\/td><\/tr>
the lowest rate in the period<\/td>4,1575<\/td>4,2678<\/td><\/tr>
the highest rate in the period<\/td>4,2778<\/td>4,3530<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Financial statements<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t